Nuvalent (NUVL) Competitors

Nuvalent logo
$78.82 +0.89 (+1.14%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NUVL vs. ONC, TEVA, BGNE, SMMT, ITCI, VTRS, GMAB, MRNA, RDY, and SRPT

Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.

Nuvalent vs.

Nuvalent (NASDAQ:NUVL) and Beigene (NASDAQ:ONC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Nuvalent has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuvalentN/AN/A-$126.22M-$3.47-22.46
Beigene$2.46B9.18-$881.71M-$8.24-28.02

In the previous week, Nuvalent and Nuvalent both had 3 articles in the media. Nuvalent's average media sentiment score of 1.05 beat Beigene's score of 0.77 indicating that Nuvalent is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvalent
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beigene
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nuvalent presently has a consensus target price of $112.36, indicating a potential upside of 44.19%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than Beigene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvalent
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
Beigene
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 48.6% of Beigene shares are owned by institutional investors. 12.5% of Nuvalent shares are owned by company insiders. Comparatively, 7.4% of Beigene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvalent has a net margin of 0.00% compared to Beigene's net margin of -25.94%. Beigene's return on equity of -25.12% beat Nuvalent's return on equity.

Company Net Margins Return on Equity Return on Assets
NuvalentN/A -28.63% -27.15%
Beigene -25.94%-25.12%-14.95%

Nuvalent received 43 more outperform votes than Beigene when rated by MarketBeat users.

CompanyUnderperformOutperform
NuvalentOutperform Votes
43
78.18%
Underperform Votes
12
21.82%
BeigeneN/AN/A

Nuvalent has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Beigene has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Summary

Nuvalent beats Beigene on 13 of the 16 factors compared between the two stocks.

Get Nuvalent News Delivered to You Automatically

Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUVL vs. The Competition

MetricNuvalentPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.54B$6.84B$5.76B$9.22B
Dividend YieldN/A2.90%5.27%4.00%
P/E Ratio-22.469.7126.2219.45
Price / SalesN/A290.45456.5777.34
Price / CashN/A75.4646.0638.90
Price / Book7.125.537.355.05
Net Income-$126.22M$123.46M$3.19B$222.81M
7 Day Performance-6.00%3.13%2.64%1.94%
1 Month Performance2.76%2.14%4.00%1.48%
1 Year Performance-9.60%1.28%22.12%16.47%

Nuvalent Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUVL
Nuvalent
2.62 of 5 stars
$78.82
+1.1%
$112.36
+42.6%
-9.6%$5.60BN/A-22.7140Upcoming Earnings
Positive News
ONC
Beigene
N/A$219.67
-1.7%
N/AN/A$21.47B$2.46B-26.6610,600News Coverage
Positive News
TEVA
Teva Pharmaceutical Industries
3.156 of 5 stars
$16.82
-0.1%
$23.57
+40.2%
+24.7%$19.05B$16.54B-11.6037,851Gap Up
BGNE
BeiGene
1.7604 of 5 stars
N/A$253.69
+∞
N/A$18.03B$3.32B-22.429,000
SMMT
Summit Therapeutics
2.4528 of 5 stars
$20.50
+1.9%
$33.57
+63.8%
+321.5%$15.12B$700,000.00-73.21110Gap Up
ITCI
Intra-Cellular Therapies
4.1283 of 5 stars
$127.12
+0.1%
$103.62
-18.5%
+69.0%$13.52B$612.78M-146.11560Analyst Forecast
Short Interest ↑
VTRS
Viatris
3.3864 of 5 stars
$10.62
-1.0%
$13.67
+28.7%
-17.3%$12.68B$15.43B-14.3538,000
GMAB
Genmab A/S
4.8409 of 5 stars
$18.69
-1.6%
$45.20
+141.8%
-25.8%$12.37B$2.39B18.152,204Earnings Report
Short Interest ↓
Analyst Revision
News Coverage
MRNA
Moderna
4.8475 of 5 stars
$31.87
-2.2%
$67.26
+111.1%
-62.7%$12.26B$6.85B-5.485,600Analyst Downgrade
RDY
Dr. Reddy's Laboratories
2.9912 of 5 stars
$13.83
-0.5%
$17.00
+23.0%
-9.9%$11.54B$3.35B22.0127,048
SRPT
Sarepta Therapeutics
4.5456 of 5 stars
$112.74
+0.8%
$178.71
+58.5%
-19.8%$10.77B$1.24B90.191,314Gap Down

Related Companies and Tools


This page (NASDAQ:NUVL) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners